The use of interim buprenorphine in people on a waiting list to enter treatment for opioid abuse resulted in dramatically less illicit opioid use than in people without interim therapy, according to a study that was highlighted in a letter to the editor of the The New England Journal of Medicine. The primary outcome of the study was the percentage of urine specimens that tested negative for illicit opioids in 25 patients who received the opioid dependence drug buprenorphine (Suboxone, Indivior) and in 25 controls. At four weeks, 88 percent of the treated group tested negative for opioids, compared with zero in the control group. Those numbers continued to improve as the interim period continued.
Further coverage from Pain Medicine News here.